BAGSVAERD, DENMARK -- 11/09/09 --
On 7 August 2009 Novo Nordisk initiated
its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 2.4 billion in the period from 10 August 2009 to 18
December 2009.
Since the announcement as of 2 November 2009, the following
transactions have been made under the programme:
Number of shares Average Transaction
purchase price value, DKK
Accumulated, last
announcement 4,669,099 1,490,518,113
2 November 2009 75,000 315.9100 23,693,250
3 November 2009 75,000 316.9650 23,772,375
4 November 2009 75,000 323.8510 24,288,825
5 November 2009 80,000 324.2290 25,938,320
6 November 2009 115,000 320.5820 36,866,930
Accumulated under the
programme 5,089,099 1,625,077,813
Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 57,850 B shares in the
period from 2 November 2009 to 6 November 2009. The shares in these
transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of
29,838,977 treasury shares, corresponding to 4.8% of the share
capital. The total amount of shares in the company is 620,000,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 67 / 2009
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
